Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics Corp is poised for significant growth driven by a robust emphasis on its plasma and hospital segments, which have demonstrated strong sales trajectories, including a notable 23.2% growth in plasma (excluding CSL) and 13.0% in Blood Management Technologies. The company is expected to sustain mid-single-digit growth rates, bolstered by accelerating revenue from non-CSL Plasma and double-digit growth from its hospital product offerings, promising improved operating margins and earnings. In addition, Haemonetics’s strategic focus on high-growth MedTech products and potential accretive acquisitions indicates a solid pathway for maintaining a favorable financial outlook amid evolving market dynamics.

Bears say

Haemonetics Corp's outlook has turned negative due to anticipated declines in its Interventional Technologies segment, which is expected to negatively impact overall gross margins given its historically high profit levels. Revenue growth projections have shifted to the low-single digits, with challenges in both the plasma and hospital segments contributing to lower-than-expected operating margins and earnings per share. Additionally, increased competition in the vascular closure device market raises concerns regarding the sustainability of Haemonetics's growth trajectory, further raising the risk of multiple compression for its shares.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jan 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.